| Autor: |
Cannon, Christopher P., Henry, Timothy D., Schweiger, Marc J., Haugland, J. Mark, McKendall, George R., Shah, Prediman K., Gleason, Ray, McCabe, Carolyn H., Antman, Elliott M., Braunwald, Eugene |
| Zdroj: |
Journal of the American College of Cardiology; February 1995, Vol. 25 Issue: 2, Number 2 Supplement 1 p231A-232A, 2p |
| Abstrakt: |
Despite clear benefit of thrombolysis (Tlysis) and primary (1°) PTCA for acute MI, prior reports have indicated a low use of thrombolytic therapy in the U.S. Further, single center reports have suggested that mortality is up to 5 times higher when thrombolysis is not given. To evaluate the management and outcome of acute MI in 1994, we conducted a registry in 20 hospitals (16 with l° PTCA capability) and prospectively identified allconsecutive patients (ptsl presenting with acute MI and ST segment elevation or new LBBB. A total of 587 pts were identified, 200 were enrolled in the TIMI 9 thrombolytic trial of hirudin vs. heparin, and 387 in the TIMI 9 Registry. Tlysis was given to 356 of 587 (60.7%) pts (of whom 200/356 (56%) were enrolled in TIMI 9); l° PTCA was performed in 62/587 (10.5%) of the total population and medical therapy used in 169/587128.8%). Of the patients enrolled in the TIMI 9 Registry, those treated with l° PTCA were significantly younger, 60.7 years, vs. 64.9 for Tlysis and 66.1 for medical therapy(each p<0.05) and were less oftenwomen, 20.0%, vs. 36.2% and 36.1%, respectively, (each p<0.05). Time to presentation was significantly longer for medically treated pts: 13.8h vs. 4.4h for Tlysis and 3.3h for 1° PTCA (each p<0.001). Delay> 12 hours was the reason cited most often for pts not treated with thrombolysis. Inhospital mortality is shown. Recurrent MI was similar in the 3 groups, 4.2%. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
